MAP1LC3B2 Protein

MAP1LC3B2 Protein (LC3B2)

Pathway Diagram

```mermaid
flowchart TD
MAP1LC3["MAP1LC3<br/>LC3 Protein"]
ATG4B["ATG4B<br/>Protease"]
ATG_COMPLEX["ATG12-ATG5-ATG16L1<br/>Complex"]
ULK1["ULK1<br/>Kinase"]
BECN1["BECN1<br/>Beclin-1"]
SQSTM1["SQSTM1<br/>p62 Receptor"]
AUTOPHAGY["Autophagy<br/>Process"]
MITOPHAGY["Mitophagy<br/>Mitochondrial Cleanup"]
PARKIN["PARKIN<br/>E3 Ligase"]
RAPAMYCIN["Rapamycin<br/>mTOR Inhibitor"]
OXIDATIVE_STRESS["Oxidative Stress<br/>Response"]
NEURODEGENERATION["Neurodegeneration<br/>Outcome"]
AUTOPHAGY_BIOMARKER["LC3 Puncta<br/>Autophagy Biomarker"]

ULK1 -->|"initiates"| AUTOPHAGY
BECN1 -->|"regulates"| MAP1LC3
ATG4B -->|"processes"| MAP1LC3
ATG_COMPLEX -->|"conjugates"| MAP1LC3
MAP1LC3 -->|"activates"| AUTOPHAGY
MAP1LC3 -->|"binds"| SQSTM1
MAP1LC3 -->|"regulates"| ULK1
SQSTM1 -->|"targets cargo"| AUTOPHAGY
PARKIN -->|"upstream of"| MAP1LC3
MAP1LC3 -->|"enables"| MITOPHAGY
RAPAMYCIN -->|"activates"| MAP1LC3
MAP1LC3 -->|"participates in"| OXIDATIVE_STRESS
AUTOPHAGY -->|"prevents"| NEURODEGENERATION
MAP1LC3 -->|"forms"| AUTOPHAGY_BIOMARKER

MAP1LC3B2 Protein (LC3B2)

Pathway Diagram

Introduction

Map1Lc3B2 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

<div class="infobox infobox-protein"> [@mizushima2011]
<table> [@nixon2013]
<tr><th colspan="2" style="background:#e8f4ea;">MAP1LC3B2 Protein</th></tr> [@jahreiss2008]
<tr><td><b>Protein Name</b></td><td>LC3B2 (Microtubule-Associated Protein 1 Light Chain 3 Beta 2)</td></tr> [@kuma2004]
<tr><td><b>Gene</b></td><td>[MAP1LC3B2](/genes/map1lc3b2)</td></tr>
<tr><td><b>UniProt ID</b></td><td>Q9GQL5</td></tr>
<tr><td><b>PDB ID</b></td><td>2K6R, 2L7Q</td></tr>
<tr><td><b>Molecular Weight</b></td><td>14.9 kDa (16.5 kDa lipidated)</td></tr>
<tr><td><b>Subcellular Localization</b></td><td>Cytoplasm, Autophagosome, Lysosome</td></tr>
<tr><td><b>Protein Family</b></td><td>ATG8 family, MAP1 LC3 family</td></tr>
<tr><td><b>Chromosomal Location</b></td><td>12p12.1</td></tr>
<tr><td><b>Associated Diseases</b></td><td>Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, ALS, Stroke</td></tr>
</table>
</div>

Overview

MAP1LC3B2 (LC3B2) is a paralog of the well-characterized LC3B (MAP1LC3B) involved in autophagosome formation and selective autophagy. As a member of the ATG8 family, LC3B2 plays critical roles in neuronal autophagy, protein aggregate clearance, and cellular homeostasis in the brain.

LC3B2 is expressed primarily in testis and at lower levels in brain tissue, where it participates in the autophagy-lysosomal pathway. The protein undergoes post-translational lipidation (phosphatidylethanolamine conjugation) similar to other ATG8 family members, enabling its incorporation into autophagosomal membranes.

Protein Structure

Domain Architecture

| Domain | Position | Function |
|--------|----------|----------|
| Ubiquitin-like fold | 1-120 | Core ATG8 structure |
| N-terminal region | 1-28 | Membrane interaction |
| LIR (LC3-Interacting Region) docking site | 13-16 | [Autophagy](/entities/autophagy) receptor binding |
| Phosphatidylethanolamine binding | 114-120 | Membrane anchoring |
| GABARAP interaction region | Various | Protein-protein interactions |

Structural Features

• Ubiquitin-like fold: Similar to ubiquitin, ~40% identical
• Hydrophobic patches: Interaction surfaces
• N-terminal glycine: Required for lipidation
• Conserved residues: Essential for ATG7 and ATG3 interactions

Post-Translational Modifications

Expression Pattern

Brain Distribution

LC3B2 expression in the brain:

• [Neurons](/entities/neurons): Moderate expression in pyramidal neurons
• [Astrocytes](/entities/astrocytes): Lower expression
• [Microglia](/entities/microglia): Constitutive expression
• Oligodendrocytes: Myelination-related expression

Tissue Specificity

• Testis: Highest expression
• Brain: Moderate expression
• Heart, liver, kidney: Lower levels
• Developmental regulation: Increases with age

Molecular Function

Autophagosome Biogenesis

LC3B2 participates in:

Selective Autophagy

LC3B2 recognizes:

• Aggregate-prone proteins: [Huntingtin](/proteins/huntingtin-protein), [α-synuclein](/proteins/alpha-synuclein), [tau](/proteins/tau)
• Damaged organelles: Mitochondria, ER
• Pathogens: Invasive bacteria, viruses
• Ubiquitinated cargo: p62/SQSTM1, OPTN, NDP52

Protein Interactions

| Partner | Interaction Type | Function |
|---------|-----------------|----------|
| ATG7 | Thioester bond | E1 enzyme |
| ATG3 | Thioester bond | E2 enzyme |
| p62/SQSTM1 | LIR binding | Selective autophagy |
| OPTN | LIR binding | Selective autophagy |
| TRIM20 | LIR binding | Mitophagy receptor |

Role in Neurodegeneration

Alzheimer's Disease

In AD:

• Autophagy impairment: LC3B2 lipidation reduced
• Amyloid-β clearance: Role in [Aβ](/proteins/amyloid-beta) degradation
• [Tau](/proteins/tau) clearance: Autophagy-mediated [tau](/proteins/tau) removal
• Neuronal vulnerability: Autophagy defects
• Therapeutic potential: Autophagy enhancers

Parkinson's Disease

In PD:

• α-synuclein clearance: LC3B2-mediated autophagy
• Mitophagy: Mitochondrial quality control
• Leucine-rich repeat kinase 2: LRRK2 regulates autophagy
• GBA1 effects: Glucosylceramidase links to autophagy

Huntington's Disease

In HD:

• Mutant [huntingtin](genes/htt): Aggregate formation
• Autophagy induction: Clearance strategies
• Transcriptional dysregulation: LC3B2 expression affected

Amyotrophic Lateral Sclerosis

In ALS:

• Protein aggregate clearance: Impaired in ALS
• Autophagy receptors: p62, OPTN mutations
• [TDP-43](/proteins/tdp-43) pathology: Autophagy involvement

Stroke and TBI

• Ischemia: Autophagy activation
• Reperfusion injury: Protective vs. detrimental
• Neuronal death: Autophagy dysregulation

Therapeutic Implications

Autophagy-Targeting Strategies

| Approach | Agent | Status | Mechanism |
|----------|-------|--------|-----------|
| [mTOR](/entities/mtor) inhibitors | Rapamycin | Research | Autophagy induction |
| AMPK activators | Metformin | Research | Autophagy induction |
| [TFEB](/entities/tfeb) activators | Gene therapy | Experimental | Lysosomal biogenesis |
| Autophagy enhancers | Trehalose | Research | [mTOR](/mechanisms/mtor-signaling-pathway)-independent |

Clinical Applications

• Neuroprotection: Enhance aggregate clearance
• Disease modification: Target underlying pathology
• Combination therapy: With other approaches

Animal Models

Transgenic Studies

• LC3B2 knockout mice: Viable with subtle defects
• GFP-LC3 mice: Monitor autophagy in vivo
• Disease models: Cross with AD/PD models

Therapeutic Studies

• Rapamycin treatment: Reduces pathology
• Trehalose administration: Promotes clearance
• Gene therapy: ATG genes delivery

Key Publications

Background

The study of Map1Lc3B2 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

See Also

• MAP1LC3B2 Gene
• MAP1LC3A Gene
• [Autophagy Pathway](/mechanisms/autophagy-lysosome-neurodegeneration)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Protein Quality Control](/mechanisms/protein-quality-control)

External Links

• [UniProt: MAP1LC3B2](https://www.uniprot.org/uniprot/Q9GQL5)
• [PDB: LC3 Structures](https://www.rcsb.org/structure/2K6R)
• [PhosphoSitePlus: LC3B2](https://www.phosphosite.org/)

References